AlphaCentric Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

AlphaCentric Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-37,693	Closed	-$812K	–	259
2025 Q4	$812K	Buy	+37,693	New	+$732K	0.81%	27
2024 Q4	$354K	Buy	+33,650	New	+$409K	0.35%	83
2020 Q3	–	Sell	-2,500	Closed	-$20K	–	166
2020 Q2	$20K	Buy	+2,500	New	+$22K	0.01%	122

Other funds holding AVDL

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

AlphaCentric Advisors's AVDL Position: Q1 2026 in Review

AlphaCentric Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 37,693 shares — an estimated $812K sold.

AlphaCentric Advisors first reported a position in AVDL in Q2 2020 and held it in 3 quarters. The position peaked at $812K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

AlphaCentric Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
AlphaCentric Advisors sold 37,693 Avadel Pharmaceuticals shares in Q1 2026, an estimated $812K.
AlphaCentric Advisors first reported a position in Avadel Pharmaceuticals in Q2 2020 and held it in 3 quarters.
AlphaCentric Advisors's Avadel Pharmaceuticals position peaked at $812K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.